clinical trial · NCT05723198
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company·phase3·recruiting·n = 595
Areata AlopeciaAlopeciaHypotrichosisHair DiseasesSkin DiseasesPathological Conditions, AnatomicalBaricitinibPlacebo
brief summary
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
started
Feb 27, 2023
primary completion
Mar 1, 2028
completion
Feb 1, 2030
last updated
Apr 17, 2026
official title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol